Acquisition by Pomerantz Roger of 9034 shares of Viracta Therapeutics subject to Rule 16b-3
| VIRXDelisted Stock | USD 0.03 0 7.38% |
Slightly above 62% of Viracta Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Viracta Therapeutics pink sheet suggests that many investors are alarmed at this time. Viracta Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Viracta Therapeutics' earnings reports, geopolitical events, and overall market trends.
Viracta |
Filed transaction by Viracta Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Viracta Therapeutics Fundamental Analysis
We analyze Viracta Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viracta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viracta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Viracta Therapeutics is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Viracta Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Viracta Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Viracta Therapeutics could also be used in its relative valuation, which is a method of valuing Viracta Therapeutics by comparing valuation metrics with similar companies.
Peers
Viracta Therapeutics Related Equities
| RLYB | Rallybio Corp | 5.71 | ||||
| LYRA | Lyra Therapeutics | 2.60 | ||||
| BCYC | Bicycle Therapeutics | 1.98 | ||||
| ALXO | Alx Oncology | 0.95 | ||||
| TERN | Terns Pharmaceuticals | 0.80 | ||||
| LPTX | Leap Therapeutics | 0.04 | ||||
| TRVI | Trevi Therapeutics | 0.22 | ||||
| TARA | Protara Therapeutics | 0.57 | ||||
| VINC | Vincerx Pharma | 0.91 | ||||
| EYPT | Eyepoint Pharmaceuticals | 1.01 | ||||
| GLUE | Monte Rosa | 1.03 | ||||
| TNYA | Tenaya Therapeutics | 1.94 | ||||
| IGMS | IGM Biosciences | 2.24 | ||||
| INZY | Inozyme Pharma | 2.42 | ||||
| STOK | Stoke Therapeutics | 2.71 | ||||
| MREO | Mereo BioPharma | 2.78 | ||||
| CABA | Cabaletta Bio | 4.55 | ||||
| XFOR | X4 Pharmaceuticals | 6.82 | ||||
| BMEA | Biomea Fusion | 14.97 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Directory Find actively traded commodities issued by global exchanges |